- Home
- DARE
DARE
Dare Bioscience Inc.
as 11-11-2025 3:28pm EST
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.
Upcoming Earnings Alert:
Get ready for potential market movements as Dare Bioscience Inc. DARE prepares to release earnings report on 13 Nov 2025.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 28.6M | IPO Year: | N/A |
| Target Price: | $10.00 | AVG Volume (30 days): | 173.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.14 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.76 - $9.19 | Next Earning Date: | 11-13-2025 |
| Revenue: | N/A | Revenue Growth: | -99.65% |
| Revenue Growth (this year): | 5401.89% | Revenue Growth (next year): | 6257.18% |
Latest Dare Bioscience Inc. News
DARE Breaking Stock News: Dive into DARE Ticker-Specific Updates for Smart Investing
GlobeNewswire
21 hours ago
Daré Bioscience Highlights Commercial Launch Readiness for DARE to PLAY™ Sildenafil Cream; November 17th Webinar to Feature Leading Clinicians Discussing Clinical Data and Potential Impact in Women’s Sexual Health
Zacks
2 days ago
Editas Medicine (EDIT) Reports Q3 Loss, Beats Revenue Estimates
Zacks
5 days ago
Sutro Biopharma, Inc. (STRO) Reports Q3 Loss, Tops Revenue Estimates
GlobeNewswire
9 days ago
Daré Bioscience to Receive up to $300,000 to Conduct Global Contraceptive Innovation Capabilities Landscape Assessment
GlobeNewswire
5 months ago
Daré Bioscience Announces Adjournment of Annual Meeting of Stockholders
Zacks
5 months ago
Is Boston Scientific (BSX) Stock Outpacing Its Medical Peers This Year?
GlobeNewswire
5 months ago
Daré Bioscience and Rosy Wellness Announce Strategic Collaboration to Educate and Market Daré’s DARE to PLAY Sildenafil Cream
Thomson Reuters StreetEvents
6 months ago
Q1 2025 Dare Bioscience Inc Earnings Call
Compare DARE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "DARE Dare Bioscience Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.